View Cart

Biofluid Based Biomarkers in Neuropsychiatric Syndromes - The Early Career Researcher Webinar

Release: 02/27/2023
No Credits Available

Faculty-

Fabricio Ferreira de Oliveira, M.D., B.B.A, M.Sc., Ph.D.
Executive Medical Director
Elysian Clinic São Paulo, Brazil


Zahinoor Ismail, M.D. FRCPC
Professor of Psychiatry, Neurology, Epidemiology and Pathology
Hotchkiss Brain Institute and O’Brien Institute for Public Health
Cumming School of Medicine, University of Calgary


Fabrizia D'Antonio, MD, PhD
Sapienza University of Rome
Italy

Maryam Ghahremani, PhD
University of Calgary
Canada

Copyright Statement with Logo Home Office
Alzheimer's Association National Office, 225 N. Michigan Ave., Fl. 17, Chicago, IL 60601
Alzheimer's Association is a not-for-profit 501(c)(3) organization.
© 2021 Alzheimer’s Association®. All rights reserved.
Disclaimer

All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher.

Recommendations involving clinical medicine in an activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in education in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection and analysis.

This activity might describe the off-label, investigational or experimental use of medications that may exceed their FDA- approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. RUSH University Medical Center requires the speaker to disclose that a product is not labeled for the use under discussion.
Target Audience / Intended Audience This activity is intended to meet the educational needs of psychologists, primary care clinicians including internists, family physicians, radiologists, neurologists, nurse practitioners and physician assistants who are seeking additional education in the assessment, diagnosis and ongoing health care of patients with cognitive impairment and dementia.
Statement of Need / Activity Purpose

The purpose of this webinar is to enhance knowledge on the potential use of biofluid biomarkers to assess neuropsychiatric diagnoses and drug response in dementia with Lewy bodies as well as in preclinical and prodromal Alzheimer's disease.
Learning Objectives

Upon completion of this webinar you will learn:

  1. To discuss associations of biofluid biomarkers with neuropsychiatric symptoms in all stages of dementia with Lewy bodies.
  2. To establish potential associations of emerging plasma biomarkers of tauopathy with neuropsychiatric symptoms in preclinical and prodromal Alzheimer's disease.
  3. To investigate if biofluid biomarkers of neuropsychiatric syndromes can be used to assess therapeutic drug response in different stages of neurodegenerative diseases.
  4. To discuss advantages and disadvantages of plasma and cerebrospinal fluid biomarkers for research and clinical correlations.
  5. To critically analyze the neurobiological underpinnings of biofluid biomarker changes in pathological conditions leading to the
    development of diverse neuropsychiatric syndromes in different patients.
    Describe interprofessional collaboration among researchers, clinicians, and other healthcare professionals to translate research findings into clinical practice.
  6. Describe interprofessional collaboration among researchers, clinicians, and other healthcare professionals to translate research findings into clinical practice.
Method of Participation

This curriculum will take approximately 60 minutes to complete. There is no fee to participate in the activity.

For questions, contact clinicaledu@alz.org